Please ensure Javascript is enabled for purposes of website accessibility

Why IDEXX Laboratories Stock Jumped 14% in January

By John Ballard – Updated Apr 19, 2019 at 10:28AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Positive news about consumer spending helped send the company's share price up last month heading into its fourth-quarter earnings report in early February.

What happened

Shares of IDEXX Laboratories (IDXX -0.89%) jumped 14.4% last month, according to data provided by S&P Global Market Intelligence.

To be clear, there wasn't any specific news from the company to cause the stock to rise in January, but the recent market sell-off might have been overdone. In late December, there was positive news about consumer spending trends during the holidays that suggested the economy is not as bad off as analysts had thought during the fall. 

Additionally, IDEXX reported fourth-quarter earnings results on Feb. 1, and they showed the company continuing to perform well. 

A brown and white puppy curled up on the floor and sleeping.

Image source: Getty Images.

So what

IDEXX delivered organic revenue growth of 10% year over year in the fourth quarter, consistent with management's expectations. Full-year organic revenue increased 11.6% to reach $2.213 billion, which exceeded management's long-term goal of 10%. Full-year revenue was in line with analysts' expectations. 

Full-year earnings per share came in at $4.26, up 36% year over year on a constant currency basis. Analysts had expected full-year earnings of $4.20 per share. The robust growth in earnings was a result of a lower tax rate and improved operating margin. 

Now what

Management reaffirmed guidance for 2019 of organic revenue growth between 9.5% and 11% over 2018, and for earnings per share to be in the range of $4.66 to $4.78. 

In a statement, CEO Jonathan Ayers summarized the thesis for owning IDEXX stock over the long term: "Our sustained high growth reinforces the enduring long-term potential we see for our markets around the world as our customers advance their standards of care by leveraging IDEXX's unique innovations. Our global opportunity for growth is supported by evolving pet owners' attitudes, particularly with the millennial generation, toward the importance of care for their family members, and by veterinary practices deepening their appreciation for the value of diagnostics in both sick animal and preventive care."

Check out the latest IDEXX earnings call transcript.

John Ballard has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Idexx Laboratories. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

IDEXX Laboratories, Inc. Stock Quote
IDEXX Laboratories, Inc.
$331.22 (-0.89%) $-2.98

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.